


Background

- **Prostate cancer (PCa)** incidence is increasing globally.
- PSA-based screening for PCa reduces prostate cancer specific mortality, but at the cost of **overdiagnosis** and resulting overtreatment.
- In 2023, the PRostate cancer Awareness and Initiative for Screening in the European Union (**PRAISE-U**) project was launched, investigating the feasibility of PCa screening within Europe (EU) (<https://uroweb.org/praise-u>) using a **double risk stratification** algorithm.

Methods

- **5 pilot sites** in Europe (Manresa (MAN), Galicia (GAL), Poland (POL), Lithuania (LIT) and Ireland (IRE)) have implemented a **risk-based PCa screening** algorithm for men aged 50-69.
- If PSA $\geq$ 3 ng/ml, risk stratification is applied to assess the need for MRI. A second risk stratification is performed for men with PI-RADS 3.
- A total of 5,640 in MAN, 12,000 in GAL, 40,000 in POL, 10,000 in LIT and 8,000 in IRE will be invited for PSA testing.

Results



Data collection is ongoing



Participation

MAN 43%, GAL 31%, POL 6%, LIT 24%, IRE 15%




PARTICIPANTS

• AVERAGE INCOME

MAN 87%, GAL 58%, POL 49%, LIT 68%, IRE 49%

• MARRIED

MAN 70%, GAL 72%, POL 80%, LIT 79%, IRE 79%



PSA $\geq$ 3 ng/ml

MAN 10%, GAL 10%, POL 16%, LIT 13%, IRE 13%



RISK STRATIFICATION 1

40-50% of men with PSA $\geq$ 3 ng/ml do not require MRI



RISK STRATIFICATION 2

45% of men with PI-RADS 3 do not require biopsy

Conclusion

- PRAISE-U is the first **population-based PCa screening initiative** in **Europe** using double risk stratification, and early data indicate the algorithm's **feasibility**. This approach shows a **reduction** in the number of **unnecessary MRIs** and **biopsies**. However, **participation** in the screening program remains **limited**, highlighting the need for targeted strategies to improve uptake. The insights gained from PRAISE-U offer valuable guidance for future screening initiatives.

The project leading to this application has received funding from the EU4Health programme under Grant Agreement n° 101101217. Co-Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them